Companies › Silence Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SLN124 siRNA targeting TMPRSS6 mRNA | TMPRSS6 | Phase 1 | Polycythemia Vera | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05499013 | SLN124 | Phase 1 | Polycythemia Vera | Oncology | Mar 2030 |
Cash and short-term investments of $72m on 2026-06-30; operating cash outflow about $29m a year; runway about 30 months at that burn, to Jan 2029
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.